INTERCEPT PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2011 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Intercept Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2011 to Q3 2023.
  • Intercept Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2023 was -$2.79M, a 101% decline year-over-year.
  • Intercept Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2023 was -$61.6M, a 130% decline year-over-year.
  • Intercept Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $222M.
  • Intercept Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$91.4M, a 66.7% increase from 2020.
  • Intercept Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$275M, a 20.3% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$61.6M -$2.79M -$270M -101% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $209M -$5.86M +$1.67M +22.1% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $207M -$32.1M -$14.9M -85.9% Jan 1, 2023 Mar 31, 2023 10-Q 2023-04-27
Q4 2022 $222M -$20.8M +$15.5M +42.6% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-02
Q3 2022 $206M $267M +$271M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$64.7M -$7.53M +$3.57M +32.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$68.3M -$17.3M +$23.1M +57.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-27
Q4 2021 -$91.4M -$36.3M +$15.9M +30.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$107M -$3.63M +$62.8M +94.5% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-02
Q2 2021 -$170M -$11.1M +$52.2M +82.5% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-02
Q1 2021 -$222M -$40.4M +$52.6M +56.5% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-02
Q4 2020 -$275M -$52.1M +$46M +46.9% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$321M -$66.5M +$18.4M +21.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$339M -$63.3M +$8.14M +11.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$347M -$93M -$2.71M -3.01% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$345M -$98.2M -$10.2M -11.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$335M -$84.8M -$20.4M -31.6% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$314M -$71.4M +$3.77M +5.02% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$318M -$90.3M -$8.68M -10.6% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$309M -$88M +$23.3M +20.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-25
Q3 2018 -$333M -$64.5M +$8.15M +11.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-25
Q2 2018 -$341M -$75.2M +$11.4M +13.1% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-25
Q1 2018 -$352M -$81.6M +$8.34M +9.27% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-25
Q4 2017 -$360M -$111M +$8.77M +7.31% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 -$369M -$72.6M +$16.2M +18.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 -$385M -$86.6M -$9.27M -12% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 -$376M -$89.9M +$36.7M +29% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 -$413M -$120M -$31.8M -36% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-28
Q3 2016 -$381M -$88.8M -$37.9M -74.5% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-28
Q2 2016 -$343M -$77.3M -$29.4M -61.4% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-28
Q1 2016 -$314M -$127M -$87.3M -222% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-28
Q4 2015 -$226M -$88.3M -$53.4M -153% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$173M -$50.9M -$15.1M -42% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$158M -$47.9M -$81.4M -243% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 -$76.6M -$39.4M +$207M +84% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$283M -$34.8M -$22.5M -182% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-29
Q3 2014 -$261M -$35.8M -$4.11M -12.9% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-29
Q2 2014 -$257M $33.5M +$46.9M Apr 1, 2014 Jun 30, 2014 10-K 2016-02-29
Q1 2014 -$304M -$246M -$236M -2310% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-29
Q4 2013 -$67.8M -$12.4M +$18.3M +59.7% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-02
Q3 2013 -$86.1M -$31.7M -$26.6M -512% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-02
Q2 2013 -$59.6M -$13.5M -$8.39M -165% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-02
Q1 2013 -$51.2M -$10.2M -$7.53M -281% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-02
Q4 2012 -$43.6M -$30.7M -$27M -742% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-14
Q3 2012 -$16.6M -$5.19M -$2.35M -82.6% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-14
Q2 2012 -$14.3M -$5.09M -$2.17M -74.3% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-14
Q1 2012 -$12.1M -$2.68M +$653K +19.6% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-14
Q4 2011 -$12.7M -$3.65M Oct 1, 2011 Dec 31, 2011 10-K 2013-04-01
Q3 2011 -$2.84M Jul 1, 2011 Sep 30, 2011 10-K 2013-04-01
Q2 2011 -$2.92M Apr 1, 2011 Jun 30, 2011 10-K 2013-04-01
Q1 2011 -$3.33M Jan 1, 2011 Mar 31, 2011 10-K 2013-04-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.